

1 Longitudinally extensive 2 transverse myelitis as the first 3 manifestation of probable 4 neurosarcoidosis - case report

5 Paula Olszewska^{1*}, Maciej Olszewski², Oskar
6 Bożek³, Łukasz Mazurek⁴, Tomasz Paleczny⁵,
7 Krzysztof Wierzbicki²

European Journal of Medical Case Reports

Volume XX(XX):XX-XX

DOI: XXXX



This is an open access article distributed in accordance with the Creative Commons Attribution (CC BY 4.0) license: <https://creativecommons.org/licenses/by/4.0/> which permits any use, Share — copy and redistribute the material in any medium or format, Adapt — remix, transform, and build upon the material for any purpose, as long as the authors and the original source are properly cited. © The Author(s) 2026

9 ABSTRACT

10 **Background:** Sarcoidosis, as a rare disease, affects 0.01% of the population; involvement of the central nervous system (CNS) is
11 even less common.

12 **Case presentation:** A 46-year-old man suffering from ulcerative colitis and epilepsy was hospitalized in the neurology department
13 due to progressive, ascending paresthesia and quadriplegia accompanied by sphincter and balance disorders. Magnetic
14 resonance imaging revealed extensive edematous changes extending from the medulla oblongata to the Th7 level and multiple
15 enlarged mediastinal lymph nodes. Diagnostic workup was expanded to include a contrast-enhanced computed tomography
16 scan of the chest, which revealed numerous enlarged lymph nodes in the mediastinum and scattered small nodular lesions in the
17 lung parenchyma. After performing a histopathological examination of the subcarinal lymph node biopsy material, a diagnosis
18 of sarcoidosis was made. The patient was diagnosed with longitudinal extensive transverse myelitis in the course of probable
19 neurosarcoidosis and was treated showed clinical improvement following treatment.

20 **Conclusion:** Although CNS involvement is not a common manifestation of this disease, immediate medical attention is necessary
21 if it occurs. The management of patients with neurosarcoidosis requires a multidisciplinary approach, which improves the
22 patient's chances of achieving long-term remission.

23 **Keywords:** case report, LETM, neurosarcoidosis, sarcoidosis, ulcerative colitis.

24 **Type of Article:** CASE REPORT **Specialty:** Neurology
25 **Correspondence to:** Paula Olszewska
26 *Department of Allergology and Clinical Immunology, Medical
27 University of Silesia, Katowice, Poland.
28 E-mail: paula.olszewska10@gmail.com
29 Full list of author information is available at the end of the article.

Received: 11-Jun-2026 **30**
Revised (1): 09-Sep-2026 **31**
Revised (2): 13-Sep-2026 **32**
Accepted: 25-Sep-2026 **33**

34 Background

35 Sarcoidosis is a multisystemic immune-mediated gran-
36 ulomatous disease. Its etiology is not yet fully under-
37 stood [1]. This disease is characterized by granulomatous
38 inflammation of the affected organs, most commonly the
39 lungs (90%), skin (15%), eyes (10%-30%), liver (20%-
40 30%), lymph nodes (10%-20%), or, much less frequently,
41 the nervous system (5%-15%) [2,3]. It affects young
42 adults (with peak incidence in the third and fourth dec-
43 ades of life) and occurs at a rate of approximately 10-20
44 per 100,000 people [1,2].

45 A postmortem study of patients published in 2017 indi-
46 cates that 34% of patients with systemic sarcoidosis also
47 had neurosarcoidosis (NS) [3]. Sarcoidosis can affect the
48 spinal cord through several mechanisms, including infil-
49 tration of the spinal cord parenchyma, meninges, epidural
50 space, or extramedullary tissues, compressing the spinal
51 cord [4,5].

52 A definitive diagnosis of NS is made in a small percent-
53 age of patients, because it requires histological confirmation

of non-caseating granulomas in the affected nervous sys- **54**
tem tissue. A probable diagnosis is defined by evidence **55**
of nervous system inflammation on magnetic resonance **56**
imaging (MRI) (trident sign on axial images) or in cerebro- **57**
spinal fluid (no specific markers for the onset of NS have **58**
been identified, but in the majority of patients, cerebrospi- **59**
nal fluid analysis reveals pleocytosis and elevated protein **60**
levels) combined with evidence of systemic sarcoidosis. **61**
Possible NS is defined by clinical suspicion and the exclu- **62**
sion of other diagnoses, but without meeting the aforemen- **63**
tioned criteria [3–5]. **64**

MRI is the method of choice when a central nervous **65**
system (CNS) - occupying lesion is suspected. Gadolinium **66**
enhancement is not sufficiently specific for NS, but it is a **67**
helpful marker of active sarcoidosis in the CNS, has value **68**
as a biomarker of treatment response, and is crucial for **69**
clinical decision-making [6–8]. **Longitudinally exten-** **70**
sive transverse myelitis (LETM) diagnosis on MRI is **71**
supported by a submedullary gadolinium enhancement **72**
pattern involving ≥ 2 spinal segments and persistence of **73**

enhancement for >2 months despite treatment. In patients with subacute myelitis, central canal enhancement and submedullary enhancements resembling a triangle on axial spinal cord MRI should raise suspicion of NS [4–7].

Case presentation

A 46-year-old man with a history of ulcerative colitis (UC) (treated with vedolizumab) and epilepsy was hospitalized in September 2024 in the neurology department of another hospital due to progressive, ascending paresthesia and quadriplegia accompanied by sphincter and balance disorders. Upon admission, a neurological examination revealed quadriplegia, a wide-based, ataxic gait, quadriparetic ataxia predominantly affecting the upper extremities, diminished superficial sensation in the lower and upper extremities and the trunk, and urinary dysfunction. Laboratory tests did not reveal any inflammatory parameters (no leukocytosis, normal CRP). Viral diseases and syphilis infection were excluded (HIV antigen, HBS antigen - negative, anti-HCV antibodies, antibodies against *Treponema pallidum* - negative). Cerebrospinal fluid analysis (CSF) revealed glucose 2,5 mmol/l (serum glucose level was not determined), cytosis (253 cells/ μ l; 99% mononuclears - monocytes and lymphocytes, 1% polymorphonuclears - neutrophils and eosinophils) and elevated protein concentration (216 mg/dl). Contrast enhanced magnetic resonance imaging (MRI) of the brain and spinal cord in the cervical (C) and thoracic (Th) segments revealed spinal cord edema extending from the medulla oblongata to the Th 7 segment. Additionally, the spinal cord enlarged by edema caused compression of the spinal cord in the cervical segment (Figure 1).



Figure 1. Sagittal section of spinal cord edema extending from the medulla oblongata to Th segments.

After intravenous contrast administration, there was strong enhancement in the posterior portion of the cord involving the posterior funiculus bilaterally, extending approximately 90 mm to the C2 to C6 levels (Figure 2).

Edematous or demyelinating changes throughout the entire spinal cord, extending from the Th1 to the Th7 level, encompassing the entire mid-spinal cord. Below, the areas were heterogeneous, partially involving the cord. The signal intensity of the gray and white matter of the brain was normal. Differential diagnosis of the spinal cord lesions included Guillain-Barré syndrome, Lyme disease, and NS.

Based on the above findings, a diagnosis of unspecified encephalomyelitis was made. The patient was initially treated with systemic steroid therapy (cumulative dose of methylprednisolone – 3 g). Due to a slow response to glucocorticoid therapy, the patient's treatment was modified to include immunoglobulins (human nonspecific immunoglobulin - 30 g per day for 5 days, cumulative dose 150 g). As a continuation of treatment, chronic oral




Figure 2. A cross-section of C spine, trident sign visible on an axial scan after gadolinium enhancement,


steroid therapy (10 mg prednisone in gradually reduced doses for 1 month) was recommended. The patient underwent neurological rehabilitation and was discharged with a significant improvement in his clinical condition. The micturition disturbances resolved, the ataxic symptoms diminished, and he was moving more efficiently.

In January 2026, the patient was admitted to the Neurology Department of the Silesian Hospital in Cieszyn for further investigation of the etiology of the previously described inflammation. A neurological examination revealed exotropia of the left eye (a persistent symptom, post-corrective surgery), quadriparesis predominantly affecting the lower limbs, and hypoesthesia in the forearms and from the level of the costal arch (Th7). The patient underwent numerous laboratory tests, including virological tests (HIV, HCV, HBV serum levels, multiplex PCR from cerebrospinal fluid - negative) ruling out bacterial diseases (syphilis - VDRL, tuberculosis - TB-IGRA, Lyme disease - intrathecal antibody production negative), systemic diseases (antinuclear antibodies present, cytoplasmic fluorescence type 1:100, granular 1:320, anti-dsDNA - negative). Calcium and vitamin D serum levels were normal. Tumor markers (Ca-15.3, Ca-19.9, CEA) were negative; anti-GAD, antibodies against antineuronal diseases (anti-NMDA, anti-AMPA1, anti-AMPA2, anti-GABAR B1/B2, anti-LGI1, anti-CASPR2), anti-MOG and anti-aquaporin 4 antibodies detected by the cell-based assay were absent. A repeat lumbar puncture revealed normalized cytosis (5 cells/ul), normal glucose level (49 mg/dl, serum level 88 mg/dl), and a slightly elevated protein concentration (63.2 mg/dl). CSF culture revealed contamination with saprophytic bacteria (*Staphylococcus hominis*).


Contrast-enhanced head MRI did not reveal inflammatory lesions. The contrast-enhanced MRI of C and Th spine revealed thoracic cord with a subtle zone of increased signal in T2 and STIR sequences extending dorsally from the Th3 to Th7 level. A similar zone was observed at the Th10 to Th12 levels. Additionally, MRI revealed multiple enlarged mediastinal lymph nodes on the coronal and transverse scans. At the suggestion of the referring radiologist, a contrast-enhanced chest computed tomography (CT) scan was performed. It revealed numerous enlarged lymph nodes in mediastinum (Figure 3).



Figure 3. A. sagittal section of Th spine, MRI images of enlarged mediastinal lymph nodes



B. sagittal section of C spine, strong enhancement in the posterior portion of the cord after contrast administration.



B. longitudinal section of thoracic cavity, CT scan images of numerous enlarged lymph nodes in mediastinum

The findings, in conjunction with the clinical presentation, were consistent with changes typical of sarcoidosis. For this reason, the patient continued diagnostic evaluation at the Pulmonary Diseases Department of the Silesian Hospital in Cieszyn. During the stay, a lung X-ray examination and numerous lung function tests were performed (*transfer factor of the lung for carbon monoxide*, spirometry, and whole-body plethysmography), which were normal. During a bronchoscopy combined with endobronchial ultrasound, a subcarinal lymph node was biopsied and subjected to histopathological examination. Acid-fast bacilli smear and periodic acid-Schiff staining were negative. Examination of the obtained tissue revealed small lymphocytic infiltrates and small granulomas composed of epithelioid histiocytes. Immunochemical testing revealed CK (–), CD68 (+), and LCA (+) in these granulomas – which indicates that the image may be consistent with sarcoidosis. The patient also underwent an ophthalmological consultation – no ophthalmological complications associated with sarcoidosis were found. The neurological disorders described upon admission persisted. Based on the comprehensive diagnostic workup, the patient was diagnosed with LETM in the context of probable NS.

The patient was then referred to a gastroenterologist to determine further treatment for UC. Due to the coexistence of UC and sarcoidosis, a history of glucocorticoid intolerance, and hepatitis following azathioprine use, the patient was most likely considered for treatment with one of the tumor necrosis factor (TNF) inhibitors.

The patient currently resides in Spain, where he and his family have moved. Since May 2026, he is being treated with infliximab with good results. Sensory disturbances in his limbs persist, and neuropathic pain occasionally develops.

Discussion

According to Clinical Criteria for a Diagnosis of Neurosarcoidosis [8], the described patient meets the criteria for probable NS (clinical presentation and diagnostic evaluation suggest NS – MRI and CT findings typical for granulomatous inflammation after exclusion of other causes; pathologic confirmation of systemic granulomatous disease).

When choosing a course of treatment for NS, it is important to assess the benefit–risk ratio and consult with specialists in other fields to ensure that treatment addresses sarcoidosis involving other organs [7]. In more severe cases, when there is an incomplete response to GCS treatment or when there are specific concerns about adverse effects, early use of TNF inhibitors is being considered [4]. Among the TNF inhibitors available in Poland, sarcoidosis can be treated with infliximab or adalimumab [9,10]. Current ECCO guidelines recommend anti-TNF drugs for inducing remission in moderate to severe UC [9,10]. In sarcoidosis, TNF- α also plays a crucial role in

the formation and maintenance of granulomas, so inhibiting TNF- α may lead to resolution of the granulomatous process [9].

Monitoring the response to treatment includes a medical history, physical examination, and typically MRI scans with and without contrast, which can detect worsening or recurrence of the disease before clinical symptoms appear [4,7,11].

It is possible that the disease may resolve, and some patients may be able to discontinue treatment, but there is a high (72%) risk of relapse after stopping therapy [4,7].

Conclusion

A broad differential diagnosis is important in the diagnosis of inflammatory lesions in the CNS. Rare diseases, such as sarcoidosis, should also be considered. Making an accurate diagnosis is crucial, primarily to enable the initiation of targeted treatment while also taking into account any co-existing conditions.

Acknowledgment

Sincere thanks to the patient for his assistance in the creation of this work.

Whats new?

NS is a rare complication of sarcoidosis. It is particularly important to note that neurological symptoms are extremely rare as the initial manifestation of sarcoidosis and require prompt and targeted intervention to limit granulomatous inflammation.

List of Abbreviations

Anti-AMPA1	Anti-AMPA receptor 1 antibodies	265
Anti-AMPA2	Anti-AMPA receptor 2 antibodies	266
Anti-CASPR	Anti-contactin-associated protein like 2 antibodies,	267
		268
Anti-dsDNA	Anti-double-stranded DNA antibodies	269
Anti-GABA-RB1/B2	Anti-GABA-B receptor B1/B2 antibodies	270
Anti-GAD	Anti-glutamic acid decarboxylase antibodies	271
Anti-LGI1	Anti-leucine-rich-glioma-inactivated 1 antibodies	272
		273
Anti-MOG	Anti-mielin oligodendrocyte glycoprotein antibodies	274
		275
Anti-NMDA	Anti-N-methyl-D-aspartate receptor antibodies	276
		277
C	Cervical	278
CD68	Cluster of differentiation 68	279
CEA	Carcinoembryonic antigen	280
Ca 15.3	Cancer marker 15.3	281
Ca 19.9	Cancer marker 19.9	282
CSF	Cerebrospinal fluid	283
CT	Computed tomography	284
HbsAg	Hepatitis B antigen	285
HCV	Hepatitis C virus	286
HIV	Human immunodeficiency virus	287
LCA	Leukocyte common antigen	288
LETM	Longitudinally extensive transverse myelitis	289
MRI	Magnetic resonance imaging	290
NS	Neurosarcoidosis	291

292	TB-IGRA	Tuberculosis interferon-gamma release assay
293	Th	Thoracic
294	TNF	Tumor necrosis factor
295	UC	Ulcerative colitis
296	VDRL	Venereal disease research laboratory

297 **Conflict of interest**

298 The authors declare that there is no conflict of interest regard-
299 ing the publication of this article.

300 **Funding**

301 None.

302 **Consent for publication**

303 Written consent was obtained from the patient for the case
304 report and the inclusion of medical imaging.

305 **Ethical Approval**

306 Ethical approval is not required for anonymous case reports.

307 **Author details**

308 Paula Olszewska¹, Maciej Olszewski², Oskar Bożek³, Łukasz
309 Mazurek⁴, Tomasz Paleczny⁵, Krzysztof Wierzbicki²

310 1. Department of Allergology and Clinical Immunology, Medical
311 University of Silesia, Katowice, Poland

312 2. Department of Neurology, Silesian Hospital in Cieszyn,
313 Cieszyn, Poland

314 3. Department of Radiology and Nuclear Medicine, Faculty of
315 Medical Sciences in Katowice, Medical University of Silesia,
316 Katowice, Poland

317 4. Tomograf Sp. z o.o. Independent Diagnostic Imaging Unit

318 5. Diagnostic Imaging Department, Silesian Hospital in Cieszyn,
319 Cieszyn, Poland

320 **References**

- 321 1. Joubert B, Chapelon-Abric C, Biard L, Saadoun D, Demeret
322 S, Dormont D, et al. Association of prognostic factors and
323 immunosuppressive treatment with long-term outcomes
324 in neurosarcoidosis. JAMA Neurol. 2017;74(11):1336–44.
325 <https://doi.org/10.1001/jamaneurol.2017.2492>
326 2. Brito-Zerón P, Kostov B, Superville D, Baughman RP,
327 Ramos-Casals M; Autoimmune Big Data Study Group.

- Geoepidemiological big data approach to sarcoidosis: geo-
graphical and ethnic determinants. Clin Exp Rheumatol.
2019;37(6):1052–64. 328
329
330
3. Fritz D, van de Beek D, Brouwer MC. Clinical features,
treatment and outcome in neurosarcoidosis: systematic
review and meta-analysis. BMC Neurol. 2016;16(1):220. 331
332
333
<https://doi.org/10.1186/s12883-016-0741-x> 334
4. Bradshaw MJ, Pawate S, Koth LL, Cho TA, Gelfand JM.
Neurosarcoidosis: pathophysiology, diagnosis, and
treatment. Neurol Neuroimmunol Neuroinflamm. 335
2021;8(6):e1084. <https://doi.org/10.1212/NXI.0000000000001084> 336
337
338
5. Westendorp WF, van de Beek D, Brouwer MC.
Neurosarcoidosis: a review from diagnosis and future per-
spectives. EclinicalMedicine. 2025;90:103653. <https://doi.org/10.1016/j.eclinm.2025.103653> 339
340
341
342
6. Shen J, Lackey E, Shah S. Neurosarcoidosis: Diagnostic
Challenges and Mimics A Review. Curr Allergy Asthma
Rep. 2023;23(7):399–410. <https://doi.org/10.1007/s11882-023-01092-z> 343
344
345
346
7. Kidd DP. Neurosarcoidosis: clinical manifestations, investi-
gation and treatment. Pract Neurol. 2020;20(3):199–212. 347
348
349
<https://doi.org/10.1136/practneurol-2019-002349> 350
8. Stern BJ, Royal W 3rd, Gelfand JM, Clifford DB, Tavee
J, Pawate S, et al. Definition and consensus diagnos-
tic criteria for neurosarcoidosis: from the neurosar-
coidosis Consortium Consensus Group. JAMA Neurol. 351
2018;75(12):1546–53. <https://doi.org/10.1001/jamaneurol.2018.2295> 352
353
354
355
9. Chaianarm S, Satiraphan P, Apiraksattaykul N,
Jitprapaikulsan J, Owattanapanich W, Rungjirajittranon
T, et al. Infliximab in neurosarcoidosis: a systematic
review and meta-analysis. Ann Clin Transl Neurol. 356
2024;11(2):466–76. <https://doi.org/10.1002/acn3.51968> 357
358
359
360
10. Gisbert JP, Chaparro M, Verstockt B, Kienle P, Minozzi
S, Allocca M, et al. ECCO Guidelines on Therapeutics in
Ulcerative Colitis: medical Treatment. J Crohns Colitis. 361
2026;20(7):jjag066. <https://doi.org/10.1093/ecco-jcc/jjag066> 362
363
364
365
366
11. Arkema EV, Cozier YC. Epidemiology of sarcoido-
sis: current findings and future directions. Ther
Adv Chronic Dis. 2018;9(11):227–40. <https://doi.org/10.1177/2040622318790197> 367
368
369
370

371 **Summary of the case**

372	1	Patient (gender, age)	46-years-old male
373	2	Final Diagnosis	LETM
374	3	Symptoms	progressive, ascending paresthesia and quadriplegia accompanied by sphincter and balance disorders
375	4	Medications	GCS, IVIG, vedolizumab, TNF
376	5	Clinical Procedure	Diagnostic imaging, pharmacotherapy, biopsy
377	6	Specialty	Neurology, gastroenterology, pulmonology